This study is to collect safety and immunogenicity data for an Rift Valley Fever (RVF) vaccine

Phase 2 Safety and Immunogenicity Study of Rift Valley Fever Vaccine

A Phase 2 Open Label Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated, Dried, TSI-GSD 200, Lot 7, Run 2, in Adult Subjects at Risk of Exposure to Rift Valley Fever Virus

Phase 1 randomized, double-blind, placebo-controlled trial to evaluate safety, tolerability, pharmacokinetics (PK) and immunogenicity of IDB-011 following intramuscular (IM )administration of single ascending doses to healthy adult participants.

Study to Evaluate Safety, Tolerability and Pharmacokinetics of IDB-011

A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety Tolerability and Pharmacokinetics of IDB-011 (IDB-774+IDB-898) in Healthy Adults

Treatment Trials

Filter & Search

Clinical Trial Results

Phase 2 Safety and Immunogenicity Study of Rift Valley Fever Vaccine

Study to Evaluate Safety, Tolerability and Pharmacokinetics of IDB-011